ArticleDiscover oncology2026
Bioinformatics analysis of TRPV1 expression and its role in hepatocellular carcinoma prognosis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is among the most lethal malignancies globally, with a persistently poor prognosis due to late diagnosis and limited therapeutic options available. The transient receptor potential vanilloid 1 (TRPV1), a calcium-permeable cation channel, plays critical roles in cancer pathogenesis across several cancer types, but its role in HCC remains poorly defined.
methodsWe performed an integrative bioinformatics analysis of TRPV1 utilizing multiple public databases, including TCGA, GEO, TIMER, UALCAN, cBioPortal, LinkedOmics, and COSMIC in HCC. We examined the TRPV1 expression profile, prognostic significance, genetic alterations, DNA methylation status, co-expression networks, and correlations with immune infiltration. Single-cell RNA sequencing and drug sensitivity dataset analyses offered additional insights into its potential functional exploration.
resultsTRPV1 mRNA expression was upregulated in HCC and correlated with multiple clinicopathological features. The high expression of TRPV1 is associated with better prognostic significance for OS, DFS, DSS, and DFI. Genetic alterations in TRPV1 occurred in 6% of tumors, mostly missense mutations (16.16%). Its expression negatively correlated with promoter methylation levels. The functional enrichment analyses demonstrate an association between TRPV1 and metabolic pathways, such as vitamin D metabolism, nicotine degradation, and biosynthesis of arginine. We also found that TRPV1 was positively associated with CD4⁺ T cell infiltration but negatively correlated with CD8⁺ T cells, B cells, dendritic cells, and macrophages. Furthermore, single-cell analysis demonstrates that malignant cells and fibroblasts have predominant TRPV1 expression. Drug sensitivity profiling demonstrates a significant association of TRPV1 with multiple CTRP drugs.
conclusionsIn this study, we identified TRPV1 as a promising prognostic biomarker in HCC, associated with favorable clinical outcomes and distinct immune landscape characteristics, and a potential therapeutic target. Further mechanistic validation and clinical investigation are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.